Sellas Life Sciences Group (SLS) said Tuesday that it has met all primary endpoints in its mid-stage trial of SLS009, a CDK9 inhibitor, in patients with relapsed or refractory acute myeloid leukemia.
The mid-stage clinical trial of SLS009 is a study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels of 45 and 60 milligrams.
CDK9 is a cancer target whose activity has been shown to correlate negatively with overall survival in several cancer types.
The trial met its primary endpoint of overall response rate of at least 20%, as well as key secondary endpoints of overall survival, safety, and tolerability with strong anti-tumor activity, the company said.
Sellas said it now plans to advance SLS009 into a randomized trial that will expand into the newly diagnosed AML populations, potentially supporting a New Drug Application. Trial preparation is underway, with enrollment expected to begin by Q1.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。